At a glance

ClinicalIndex Comparison Record

Phase 3Completed

Drug / intervention

duloxetine +2 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00073411

NCT00073411Phase 3Completed

Compare CT.gov

Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depression

Eli Lilly and Company·interventional·Posted Nov 21, 2003·Updated Jul 31, 2007

In Brief

A Phase 3 clinical trial evaluating duloxetine, escitalopram, and 1 other intervention for Depression. Completed, across 1 site.

Detailed Summary

The purposes of this study are to determine: * The safety of duloxetine and any side effects that might be associated with it. * How duloxetine compares to escitalopram and placebo (an inactive ingredient)

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsDepression

CountriesUnited States

Collaborators--

Timeline

Phase 3CompletedFinished

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartNov 2003

First PostedNov 2003

Study CompletionMay 2005

TodayJul 2026

First PostedNov 21, 2003

Enrollment StartNov 1, 2003

Study CompletionMay 1, 2005

TodayJul 2, 2026

Posted 22.6 years ago

Interventions

duloxetinedrug

escitalopramdrug

placebodrug